☰

Tsui-Fen Chou, Ph.D. - Publications

Affiliations: 
2006 University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
development of approaches that will deliver anticancers drug, proteins and nucleic acids to cancer tissues and not normal tissues
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Wang F, Li S, Gan T, Stott GM, Flint AJ, Chou TF. Allosteric p97 inhibitors can overcome resistance to ATP-competitive p97 inhibitors for potential anti-cancer therapy. Chemmedchem. PMID 32162487 DOI: 10.1002/Cmdc.201900722  0.321
2018 LaPorte MG, Burnett JC, Colombo R, Bulfer SL, Alverez C, Chou TF, Neitz RJ, Green N, Moore WJ, Yue Z, Li S, Arkin MR, Wipf P, Huryn DM. Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97. Acs Medicinal Chemistry Letters. 9: 1075-1081. PMID 30429948 DOI: 10.1021/Acsmedchemlett.8B00372  0.323
2018 Li J, Zhang Y, Da Silva Sil Dos Santos B, Wang F, Ma Y, Perez C, Yang Y, Peng J, Cohen SM, Chou TF, Hilton ST, Deshaies RJ. Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11. Cell Chemical Biology. PMID 30146242 DOI: 10.1016/J.Chembiol.2018.07.012  0.399
2018 Srivastava AK, Govindharajulu JP, Hollingshead MG, Stotler H, Wang F, Chou T, Banfield K, Tomaino F, Stott G, Doroshow JH, Parchment RE. Pharmacodynamics of first-in-class p97 inhibitors that disrupt protein homeostasis in cancer. Journal of Clinical Oncology. 36: e14539-e14539. DOI: 10.1200/Jco.2018.36.15_Suppl.E14539  0.376
2018 Bastola P, Freudenthal B, Schaich M, Chou T, Gan T, Wang F, Chien J. Abstract A40: Specific mutations in the D1-D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-A40  0.321
2018 Sauni CT, Wang F, Kan S, Le SQ, Anderson B, Wood J, Ekins S, Chou T, Dickson P. Pilot enzyme replacement therapy with recombinant human glucosamine (N-acetyl)-6-sulfatase in mucopolysaccharidosis type IIID mouse model Molecular Genetics and Metabolism. 123. DOI: 10.1016/J.Ymgme.2017.12.340  0.306
2017 Bastola P, Wang F, Schaich MA, Gan T, Freudenthal BD, Chou TF, Chien J. Specific mutations in the D1-D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. Cell Death Discovery. 3: 17065. PMID 29367883 DOI: 10.1038/Cddiscovery.2017.65  0.333
2017 Nakasone MA, Lewis TA, Walker O, Thakur A, Mansour W, Castañeda CA, Goeckeler-Fried JL, Parlati F, Chou TF, Hayat O, Zhang D, Camara CM, Bonn SM, Nowicka UK, Krueger S, et al. Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway. Structure (London, England : 1993). PMID 29153505 DOI: 10.1016/J.Str.2017.10.007  0.347
2017 Shah R, Chou TF, Maize KM, Strom A, Finzel BC, Wagner CR. Inhibition by divalent metal ions of human histidine triad nucleotide binding protein1 (hHint1), a regulator of opioid analgesia and neuropathic pain. Biochemical and Biophysical Research Communications. PMID 28739258 DOI: 10.1016/J.Bbrc.2017.07.111  0.648
2017 Lee Y, Chou TF, Pittman SK, Keith AL, Razani B, Weihl CC. Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA Domain Ubiquitination. Cell Reports. 19: 188-202. PMID 28380357 DOI: 10.1016/J.Celrep.2017.03.030  0.316
2017 Segura-Cabrera A, Tripathi R, Zhang X, Gui L, Chou TF, Komurov K. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase. Scientific Reports. 7: 44912. PMID 28322292 DOI: 10.1038/Srep44912  0.327
2017 Perez C, Li J, Parlati F, Rouffet M, Ma Y, Mackinnon AL, Chou TF, Deshaies RJ, Cohen SM. Discovery of an Inhibitor of the Proteasome Subunit Rpn11. Journal of Medicinal Chemistry. PMID 28191850 DOI: 10.1021/Acs.Jmedchem.6B01379  0.392
2016 Bulfer SL, Chou TF, Arkin MR. p97 disease mutations modulate nucleotide-induced con-formation to alter protein-protein interactions. Acs Chemical Biology. PMID 27267671 DOI: 10.1021/Acschembio.6B00350  0.363
2014 Kato M, Chou TF, Yu CZ, DeModena J, Sternberg PW. LINKIN, a new transmembrane protein necessary for cell adhesion. Elife. 3: e04449. PMID 25437307 DOI: 10.7554/Elife.04449  0.327
2013 Zhou X, Chou TF, Aubol BE, Park CJ, Wolfenden R, Adams J, Wagner CR. Kinetic mechanism of human histidine triad nucleotide binding protein 1. Biochemistry. 52: 3588-600. PMID 23614568 DOI: 10.1021/Bi301616C  0.592
2013 Shi Y, Liu X, Calaoagan J, Samuelsson S, Chou T, Deshaies RJ, Sambucetti LC. Abstract 2146: Development of functional assays for p97/VCP inhibition. Cancer Research. 73: 2146-2146. DOI: 10.1158/1538-7445.Am2013-2146  0.351
2011 Bardaweel S, Ghosh B, Chou TF, Sadowsky MJ, Wagner CR. E. coli histidine triad nucleotide binding protein 1 (ecHinT) is a catalytic regulator of D-alanine dehydrogenase (DadA) activity in vivo. Plos One. 6: e20897. PMID 21754980 DOI: 10.1371/Journal.Pone.0020897  0.564
2011 Chou TF, Deshaies RJ. Development of p97 AAA ATPase inhibitors. Autophagy. 7: 1091-2. PMID 21606684 DOI: 10.4161/Auto.7.9.16489  0.35
2011 Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proceedings of the National Academy of Sciences of the United States of America. 108: 4834-9. PMID 21383145 DOI: 10.1073/Pnas.1015312108  0.366
2011 Birkus G, Kutty N, Frey CR, Shribata R, Chou T, Wagner C, McDermott M, Cihlar T. Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191 Antimicrobial Agents and Chemotherapy. 55: 2166-2173. PMID 21383096 DOI: 10.1128/Aac.01603-10  0.576
2011 Chou TF, Deshaies RJ. Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. The Journal of Biological Chemistry. 286: 16546-54. PMID 21343295 DOI: 10.1074/Jbc.M110.215319  0.395
2010 Bardaweel S, Pace J, Chou TF, Cody V, Wagner CR. Probing the impact of the echinT C-terminal domain on structure and catalysis. Journal of Molecular Biology. 404: 627-38. PMID 20934431 DOI: 10.1016/J.Jmb.2010.09.066  0.539
2009 Cheng J, Zhou X, Chou TF, Ghosh B, Liu B, Wagner CR. Identification of the amino acid-AZT-phosphoramidase by affinity T7 phage display selection. Bioorganic & Medicinal Chemistry Letters. 19: 6379-81. PMID 19825512 DOI: 10.1016/J.Bmcl.2009.09.067  0.547
2008 Chou TF, So C, White BR, Carlson JC, Sarikaya M, Wagner CR. Enzyme nanorings. Acs Nano. 2: 2519-25. PMID 19206287 DOI: 10.1021/nn800577h  0.642
2008 Ghosh P, Cheng J, Chou TF, Jia Y, Avdulov S, Bitterman PB, Polunovsky VA, Wagner CR. Expression, purification and characterization of recombinant mouse translation initiation factor eIF4E as a dihydrofolate reductase (DHFR) fusion protein. Protein Expression and Purification. 60: 132-9. PMID 18479935 DOI: 10.1016/J.Pep.2008.03.024  0.603
2007 Chou TF, Sham YY, Wagner CR. Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate specificity. Biochemistry. 46: 13074-9. PMID 17939685 DOI: 10.1021/Bi701244H  0.545
2007 Chou TF, Cheng J, Tikh IB, Wagner CR. Evidence that human histidine triad nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad (HIT) superfamily. Journal of Molecular Biology. 373: 978-89. PMID 17870088 DOI: 10.1016/J.Jmb.2007.08.023  0.575
2007 Chou TF, Tikh IB, Horta BA, Ghosh B, De Alencastro RB, Wagner CR. Engineered monomeric human histidine triad nucleotide-binding protein 1 hydrolyzes fluorogenic acyl-adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate. The Journal of Biological Chemistry. 282: 15137-47. PMID 17337452 DOI: 10.1074/Jbc.M606972200  0.519
2007 Chou TF, Baraniak J, Kaczmarek R, Zhou X, Cheng J, Ghosh B, Wagner CR. Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Molecular Pharmaceutics. 4: 208-17. PMID 17217311 DOI: 10.1021/Mp060070Y  0.603
2007 Chou TF, Wagner CR. Lysyl-tRNA synthetase-generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins. The Journal of Biological Chemistry. 282: 4719-27. PMID 17158446 DOI: 10.1074/Jbc.M610530200  0.593
2006 Carlson JC, Jena SS, Flenniken M, Chou TF, Siegel RA, Wagner CR. Chemically controlled self-assembly of protein nanorings. Journal of the American Chemical Society. 128: 7630-8. PMID 16756320 DOI: 10.1021/Ja060631E  0.632
2005 Chou TF, Bieganowski P, Shilinski K, Cheng J, Brenner C, Wagner CR. 31P NMR and genetic analysis establish hinT as the only Escherchia coli purine nucleoside phosphoramidase and as essential for growth under high salt conditions. The Journal of Biological Chemistry. 280: 15356-61. PMID 15703176 DOI: 10.1074/Jbc.M500434200  0.608
2004 Kim J, Chou TF, Griesgraber GW, Wagner CR. Direct measurement of nucleoside monophosphate delivery from a phosphoramidate pronucleotide by stable isotope labeling and LC-ESI(-)-MS/MS. Molecular Pharmaceutics. 1: 102-11. PMID 15832506 DOI: 10.1021/Mp0340338  0.447
Show low-probability matches.